Results 121 to 130 of about 117,026 (248)

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

open access: yesInternational Journal of Cancer, Volume 159, Issue 11, Page 2633-2652, 1 December 2026.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari   +10 more
wiley   +1 more source

Somatostatin Analogs in Acromegaly [PDF]

open access: yesThe Journal of Clinical Endocrinology & Metabolism, 2002
openaire   +2 more sources

Primary Hepatic Neuroendocrine Neoplasms: Systematic Review and Expert Pathologist Reappraisal Using the WHO 6th Edition Framework

open access: yesLiver International, Volume 46, Issue 11, November 2026.
ABSTRACT Primary hepatic neuroendocrine neoplasms (PHNENs) are exceedingly rare. Published evidence often lacks adequate clinicopathological support for a primary hepatic origin and uses inconsistent historical terminology. Previous reviews have pooled well‐differentiated neuroendocrine tumours (NETs), poorly differentiated neuroendocrine carcinomas ...
Marcello Maestri   +6 more
wiley   +1 more source

Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations

open access: yesAmerican Journal of Hematology, Volume 101, Issue 10, Page 2605-2615, October 2026.
Targeted antiangiogenic therapy with systemic bevacizumab for bleeding from acquired GI VMs was found to be safe and effective for chronic and severe bleeding from acquired vascular malformations due to idiopathic angiodysplasia, chronic liver disease, and deficiencies of von Willebrand factor, in a patient population comprised mostly of heavily ...
Nardeen E. Ayad   +5 more
wiley   +1 more source

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study. [PDF]

open access: yesJ Clin Med, 2022
Berton AM   +12 more
europepmc   +1 more source

Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single‐Arm Phase II Study

open access: yesCancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer. Somatostatin analogues, such as lanreotide, have shown efficacy in managing other neuroendocrine tumors. Retrospective studies suggest that lanreotide may induce partial response or disease stabilization in patients with advanced MCC.
Julie Charles   +23 more
wiley   +1 more source

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. [PDF]

open access: yesJ Endocrinol Invest, 2023
Machado-Alba JE   +6 more
europepmc   +1 more source

Frozen in Place: Proximity Labeling Maps Glial Interactomes Across Cell States

open access: yesGlia, Volume 74, Issue 10, October 2026.
Proximity labeling enables cell‐type‐specific and spatially resolved mapping of glial protein networks. Proximity labeling approaches provide insights into glial function under physiological and pathological conditions. ABSTRACT Glial cells, including radial glia, oligodendrocyte precursor cells (OPCs), oligodendrocytes, astrocytes, and microglia, are ...
João Baltar   +3 more
wiley   +1 more source

Editorial: Toward Prognostic Precision in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms

open access: yesCancer Control
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which encompass well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs), are a clinically and pathologically heterogeneous group of diseases ...
Muhammer Ergenç MD, FEBS   +1 more
doaj   +1 more source

Home - About - Disclaimer - Privacy